| scholarly article | Q13442814 |
| P50 | author | M. Eric Gershwin | Q73297886 |
| P2093 | author name string | Raoul Poupon | |
| E. Jenny Heathcote | |||
| Keith D. Lindor | |||
| Marshall Kaplan | |||
| Nora V. Bergasa | |||
| P2860 | cites work | Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis | Q40186249 |
| The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids | Q40513479 | ||
| The true impact of fatigue in primary biliary cirrhosis: a population study | Q40643274 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Natural history of early primary biliary cirrhosis | Q41234807 | ||
| Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial | Q41673941 | ||
| Effect of oral naltrexone on pruritus in cholestatic patients | Q41808544 | ||
| Transplantation trends in primary biliary cirrhosis. | Q42632785 | ||
| A prospective trial of colchicine for primary biliary cirrhosis | Q42659809 | ||
| Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis | Q43214926 | ||
| Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability | Q43475774 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis | Q43484548 | ||
| Induction of primary biliary cirrhosis in guinea pigs following chemical xenobiotic immunization | Q43575984 | ||
| Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? | Q43676662 | ||
| Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens | Q43693265 | ||
| Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. | Q43734578 | ||
| Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? | Q43807982 | ||
| Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid | Q43875853 | ||
| Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid | Q43893454 | ||
| Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients | Q43903202 | ||
| Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers | Q43954071 | ||
| Randomized trial of chlorambucil for primary biliary cirrhosis. | Q44093311 | ||
| Fenofibrate treatment in patients with primary biliary cirrhosis | Q44110727 | ||
| Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation | Q44169502 | ||
| Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis | Q44487597 | ||
| Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis | Q44517790 | ||
| Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. | Q44573504 | ||
| Recurrence of primary biliary cirrhosis after liver transplantation: Histologic estimate of incidence and natural history | Q44606835 | ||
| Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial | Q44679061 | ||
| When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? | Q44797408 | ||
| Natural history of pruritus in primary biliary cirrhosis | Q44797529 | ||
| Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation | Q44817502 | ||
| A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results | Q44825279 | ||
| Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis | Q44930578 | ||
| Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis | Q45002713 | ||
| The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis | Q45024371 | ||
| Quality of life in patients with primary biliary cirrhosis | Q45059665 | ||
| Mucosal immunity and primary biliary cirrhosis: presence of antimitochondrial antibodies in urine | Q45168673 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex. | Q45948332 | ||
| Fat-soluble vitamin levels in patients with primary biliary cirrhosis | Q34379099 | ||
| Characterisation of patients with a complete biochemical response to ursodeoxycholic acid | Q34408204 | ||
| Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes | Q34445524 | ||
| Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients | Q34462959 | ||
| Portal hypertension in primary biliary cirrhosis | Q34474035 | ||
| Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis | Q34594429 | ||
| An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis | Q34608494 | ||
| Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis | Q34690306 | ||
| Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years | Q34932835 | ||
| Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? | Q35030826 | ||
| Natural history of primary biliary cirrhosis. | Q35573903 | ||
| Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis | Q35573921 | ||
| Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. | Q35594405 | ||
| Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis | Q35594898 | ||
| Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. | Q35596429 | ||
| Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort | Q35596580 | ||
| Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? | Q35597224 | ||
| Opioid peptides and primary biliary cirrhosis | Q35706319 | ||
| Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort | Q35760389 | ||
| Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis | Q35760984 | ||
| Primary biliary cirrhosis: report of a focus study group | Q35894578 | ||
| Statins and hepatotoxicity: focus on patients with fatty liver | Q36079406 | ||
| Antihistamines in dermatology | Q36193211 | ||
| The autoepitope of the 74-kD mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of dihydrolipoamide acetyltransferase | Q36357621 | ||
| Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review | Q36714163 | ||
| Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses | Q36801651 | ||
| Conventional therapy of Sjogren's syndrome | Q36997278 | ||
| Pruritus and fatigue associated with liver disease: is there a role for ondansetron? | Q37099029 | ||
| Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis | Q37388003 | ||
| The pruritus of cholestasis: from bile acids to opiate agonists | Q37879905 | ||
| Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. | Q38999540 | ||
| Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals | Q39225838 | ||
| Itch in primary biliary cirrhosis: a patients' perspective | Q39325404 | ||
| Treatment of pruritus of primary biliary cirrhosis with rifampin | Q39511303 | ||
| Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis | Q39737852 | ||
| Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study | Q78554315 | ||
| The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine | Q79091520 | ||
| Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis | Q79257928 | ||
| Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy | Q79298104 | ||
| Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis | Q79438224 | ||
| Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease | Q79711877 | ||
| Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis | Q79788278 | ||
| Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis | Q80073128 | ||
| Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials | Q80215317 | ||
| Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus) | Q80311756 | ||
| Primary biliary cirrhosis | Q81246142 | ||
| Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis | Q81513622 | ||
| Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites | Q82639990 | ||
| Bone loss and reduced osteoblast function in primary biliary cirrhosis | Q93642995 | ||
| Characterization of antimitochondrial antibodies in health adults | Q46110088 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue | Q46509129 | ||
| Long-term fibrate treatment for PBC. | Q46534026 | ||
| Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial | Q46714065 | ||
| Modafinil for the treatment of fatigue in primary biliary cirrhosis | Q46735291 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment | Q46795010 | ||
| Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome | Q46852534 | ||
| Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom | Q46982754 | ||
| Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence | Q48496394 | ||
| Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis | Q49323238 | ||
| Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. | Q50684179 | ||
| Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function. | Q50711662 | ||
| Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. | Q51597355 | ||
| Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. | Q51621306 | ||
| The incidence of pruritus after epidural morphine. | Q51748346 | ||
| Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. | Q53221825 | ||
| Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. | Q53241327 | ||
| Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. | Q53711274 | ||
| Development of autoimmune hepatitis in primary biliary cirrhosis. | Q53713488 | ||
| Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. | Q54032405 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Osteoporosis in Primary Biliary Cirrhosis: A Randomized Trial of the Efficacy and Feasibility of Estrogen/Progestin | Q58311495 | ||
| Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls | Q58376324 | ||
| Effect of liver cirrhosis on the systemic availability of naltrexone in humans | Q58896381 | ||
| Sertraline as a first-line treatment for cholestatic pruritus | Q61480066 | ||
| Familial primary biliary cirrhosis reassessed: a geographically-based population study | Q61633902 | ||
| Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study | Q61854318 | ||
| Azathioprine and prognosis in primary biliary cirrhosis. | Q64903641 | ||
| A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results | Q67590480 | ||
| Topical ciclosporin in the treatment of ocular surface disorders | Q24670344 | ||
| Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 | ||
| Effect of distal splenorenal shunt on survival of patients with primary biliary cirrhosis | Q28242047 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Modafinil for excessive sleepiness associated with shift-work sleep disorder | Q28265627 | ||
| Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis | Q28289028 | ||
| A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis | Q28290430 | ||
| Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline | Q28369455 | ||
| Management of hepatocellular carcinoma | Q29616230 | ||
| Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. | Q31027142 | ||
| Consecutive occurrence of primary biliary cirrhosis and autoimmune hepatitis: a case report and review of the literature | Q32090723 | ||
| The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus | Q33280833 | ||
| Incidence of cancer in primary biliary cirrhosis: the Mayo experience | Q33601440 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis | Q33784003 | ||
| Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis | Q33851658 | ||
| Primary biliary cirrhosis: an orchestrated immune response against epithelial cells | Q33916633 | ||
| Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice | Q34223451 | ||
| Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis | Q34324928 | ||
| Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis | Q34377943 | ||
| Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects | Q67928582 | ||
| Fat-Soluble Vitamin Nutriture in primary Biliary Cirrhosis | Q68450012 | ||
| A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis | Q68505504 | ||
| Pathogenesis of steatorrhea in primary biliary cirrhosis | Q68940388 | ||
| Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival | Q69738156 | ||
| Naltrexone and hepatotoxicity | Q69880968 | ||
| Trial of penicillamine in advanced primary biliary cirrhosis | Q69887093 | ||
| Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease | Q69971289 | ||
| Vitamin E deficiency and its clinical significance in adults with primary biliary cirrhosis and other forms of chronic liver disease | Q70183282 | ||
| Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial | Q70542319 | ||
| Time course of histological progression in primary biliary cirrhosis | Q70869710 | ||
| Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
| Increased incidence of hypothyroidism in primary biliary cirrhosis | Q71065625 | ||
| A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid | Q72189521 | ||
| Improvement of cholestatic pruritus by ondansetron | Q72218628 | ||
| Primary biliary cirrhosis. Sole presentation with rampant dental caries | Q72241874 | ||
| Ondansetron for pruritus due to cholestasis | Q72379137 | ||
| American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers | Q72590133 | ||
| Major histocompatibility complex class-II alleles in primary biliary cirrhosis | Q72664892 | ||
| Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years | Q72727069 | ||
| Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis | Q72736523 | ||
| Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? | Q72800622 | ||
| Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis | Q73302312 | ||
| Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis | Q73319901 | ||
| Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial | Q73330566 | ||
| Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid | Q73401694 | ||
| Primary biliary cirrhosis, sicca complex, and dysphagia | Q73430902 | ||
| Pain as a complication of use of opiate antagonists for symptom control in cholestasis | Q73735616 | ||
| Bioavailability of four ursodeoxycholic acid preparations | Q74260266 | ||
| Open-label trial of oral nalmefene therapy for the pruritus of cholestasis | Q74310569 | ||
| Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis | Q74529900 | ||
| Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression | Q74645177 | ||
| Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 | ||
| Liver transplantation for intractable pruritus is contraindicated before an adequate trial of opiate antagonist therapy | Q77113445 | ||
| Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group | Q77221662 | ||
| Naltrexone in the treatment of alcohol dependence | Q77347366 | ||
| Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | Q77807948 | ||
| Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial | Q77872001 | ||
| Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial | Q78039888 | ||
| Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy | Q78100086 | ||
| Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study | Q78163535 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 291-308 | |
| P577 | publication date | 2009-02-11 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Primary biliary cirrhosis | |
| P478 | volume | 50 |
| Q24186229 | Q24186229 |
| Q38460458 | 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus |
| Q57929229 | A Case of Antimitochondrial Antibody Negative Primary Biliary Cirrhosis from Bangladesh and Review of Literature |
| Q37639136 | A Case of Primary Biliary Cirrhosis Mimicking Acute Hepatitis B in the Clinic, Republic of Korea |
| Q46623166 | A Mouse Model of Autoimmune Cholangitis via Syngeneic Bile Duct Protein Immunization |
| Q93190745 | A National Hospital-Based Study of Hospitalized Patients With Primary Biliary Cholangitis |
| Q40836466 | A Patient With Primary Biliary Cirrhosis Accompanied by Wilson's Disease |
| Q45069872 | A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis. |
| Q64234407 | A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis |
| Q57117681 | A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity: A Case Report |
| Q48342063 | A brief review on prognostic models of primary biliary cholangitis |
| Q40728797 | A case of primary biliary cirrhosis and autoimmune hepatitis overlap showing acute presentation and transient seropositivity for immunoglobulin G and anti-nuclear antibody |
| Q36851472 | A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab |
| Q55512501 | A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. |
| Q35490131 | A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis |
| Q33675881 | A genome-wide association study identifies six novel risk loci for primary biliary cholangitis |
| Q37468171 | A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis |
| Q53648391 | A possible involvement of endoplasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary cirrhosis. |
| Q54548926 | A possible involvement of p62/sequestosome-1 in the process of biliary epithelial autophagy and senescence in primary biliary cirrhosis. |
| Q37073143 | A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India |
| Q38637490 | A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. |
| Q36185550 | AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations |
| Q40416496 | ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries |
| Q40809932 | ACG Clinical Guideline: Liver Disease and Pregnancy |
| Q55059041 | ACG Clinical Guideline: Primary Sclerosing Cholangitis. |
| Q30454106 | ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study |
| Q36116022 | Advances in pharmacotherapy for primary biliary cirrhosis |
| Q89623409 | Aging-Related Molecular Pathways in Chronic Cholestatic Conditions |
| Q84476629 | American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis |
| Q52355268 | An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis. |
| Q54282638 | Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. |
| Q42426062 | Answers to multiple choice questions |
| Q51201875 | Anti-centromere antibody is an independent risk factor for chronic kidney disease in patients with primary biliary cirrhosis. |
| Q35008069 | Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis |
| Q36081422 | Anti-mitochondrial M2 antibody-positive autoimmune hepatitis |
| Q64095704 | Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations |
| Q42319828 | Anti-mitochondrial autoantibodies-milestone or byway to primary biliary cholangitis? |
| Q33598806 | Apamin suppresses biliary fibrosis and activation of hepatic stellate cells |
| Q47770804 | Aquaporin-1 is associated with arterial capillary proliferation and hepatic sinusoidal transformation contributing to portal hypertension in primary biliary cirrhosis. |
| Q88599326 | Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness |
| Q89339335 | Association between STAT4 polymorphisms and risk of primary biliary cholangitis: a meta-analysis |
| Q39176767 | Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis. |
| Q48134030 | Association of autoimmune hepatitis with Src homology 2 adaptor protein 3 gene polymorphisms in Japanese patients |
| Q54274187 | Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. |
| Q35990216 | Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. |
| Q37750545 | Autoantibodies as prognostic markers in autoimmune liver disease |
| Q34827471 | Autoantibodies in Chinese patients with chronic hepatitis B: prevalence and clinical associations |
| Q64263911 | Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA |
| Q33751665 | Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis |
| Q34346124 | Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. |
| Q35078109 | Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation |
| Q39010580 | Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria |
| Q35230369 | Autoimmune liver disease - are there spectra that we do not know? |
| Q91788029 | Autoimmune liver disease and the enteric microbiome |
| Q30244056 | Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. |
| Q33825348 | Autoimmunity and environment: am I at risk? |
| Q46484331 | B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid |
| Q36080972 | BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial |
| Q91431676 | Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis |
| Q39145368 | Bile acids and cardiovascular function in cirrhosis. |
| Q37666088 | Bile acids reach out to the spinal cord: new insights to the pathogenesis of itch and analgesia in cholestatic liver disease |
| Q34108895 | Biliary physiology and disease: reflections of a physician-scientist |
| Q42620850 | Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid |
| Q33641759 | Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study |
| Q33723821 | Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. |
| Q85345310 | Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA |
| Q55324101 | Biomarkers for primary biliary cholangitis: current perspectives. |
| Q26766699 | Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver |
| Q35867125 | CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis |
| Q36276815 | Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening |
| Q55237166 | Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study. |
| Q44853838 | Case Report: Ursodeoxycholic acid treatment in Niemann-Pick disease type C; clinical experience in four cases. |
| Q90262910 | Changes in the gut microbiota of mice orally exposed to methylimidazolium ionic liquids |
| Q55071942 | Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. |
| Q93140801 | Changing epidemiology and natural history of primary biliary cirrhosis |
| Q34494216 | Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. |
| Q55059313 | Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. |
| Q33821346 | Characteristics of liver fibrosis with different etiologies using a fully quantitative fibrosis assessment tool |
| Q57145981 | Characterization and treatment of persistent hepatocellular secretory failure |
| Q35637528 | Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis. |
| Q38994830 | Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8+ T cell activation |
| Q24200307 | Chlorambucil for patients with primary biliary cirrhosis |
| Q24235780 | Chlorambucil for primary biliary cirrhosis |
| Q57111104 | Cholestatic liver diseases: new targets, new therapies |
| Q90154099 | Cholestatic pruritus: Emerging mechanisms and therapeutics |
| Q36389501 | Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis |
| Q28070154 | Cirrhosis and autoimmune liver disease: Current understanding |
| Q37546867 | Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort |
| Q91795125 | Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches |
| Q55394717 | Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. |
| Q42272368 | Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona |
| Q37232721 | Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis |
| Q88300304 | Clinical connection between rheumatoid arthritis and liver damage |
| Q38941504 | Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation |
| Q38611759 | Clonal Characteristics of Paired Infiltrating and Circulating B Lymphocyte Repertoire in Patients with Primary Biliary Cholangitis |
| Q54040784 | Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. |
| Q35823397 | Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis |
| Q34668643 | Comparative proteomics study on liver mitochondria of primary biliary cirrhosis mouse model |
| Q50976613 | Comparison between real-time tissue elastography and vibration-controlled transient elastography for the assessment of liver fibrosis and disease progression in patients with primary biliary cholangitis. |
| Q44162573 | Complete spectrum of AMA-M2 positive liver disease in north India |
| Q48331749 | Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. |
| Q91644552 | Concomitant Sjögren's Syndrome Was Not Associated with a Poorer Response or Outcomes in Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cholangitis |
| Q48200680 | Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. |
| Q37501384 | Concurrent autoimmune pancreatitis and primary biliary cirrhosis: a rare case report and literature review |
| Q37102484 | Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study |
| Q46521938 | Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid |
| Q36752084 | Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q38055205 | Current pharmacotherapy for cholestatic liver disease |
| Q92190130 | Cutoff Values of Acoustic Radiation Force Impulse Two-Location Measurements in Different Etiologies of Liver Fibrosis |
| Q37993224 | Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review |
| Q33744692 | Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice |
| Q33678116 | Detection of AMA-M2 in human saliva: Potentials in diagnosis and monitoring of primary biliary cholangitis |
| Q54358503 | Detection of D-3-phosphoglycerate dehydrogenase autoantibodies in patients with autoimmune hepatitis: Clinical significance evaluation. |
| Q45932486 | Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. |
| Q89302981 | Deviations in Peripheral Blood Cell Populations are Associated with the Stage of Primary Biliary Cholangitis and Presence of Itching |
| Q28076505 | Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions |
| Q44247097 | Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba |
| Q38266358 | Diagnosis and management of primary biliary cirrhosis |
| Q51726466 | Diagnosis and management of primary sclerosing cholangitis. |
| Q39542696 | Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease? |
| Q39424761 | Diagnostic autoantibodies for autoimmune liver diseases |
| Q39096610 | Diagnostic considerations for cholestatic liver disease |
| Q34776270 | Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. |
| Q33731999 | Distinctive HLA-II association with primary biliary cholangitis on the Island of Sardinia |
| Q98779028 | Do hepatic artery infusion pumps cause recurrent pleural effusions? |
| Q38592916 | Drug treatment of pruritus in liver diseases. |
| Q89403871 | Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease |
| Q50132221 | Editorial: Itching to Know: Role of Fibrates in PBC. |
| Q47440077 | Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. |
| Q43004194 | Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study |
| Q47156253 | Elevated Liver Enzymes in Asymptomatic Patients - What Should I Do? |
| Q33962221 | Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver |
| Q51560561 | Elevation of Vδ1 T cells in peripheral blood and livers of patients with primary biliary cholangitis. |
| Q38744215 | Emerging drugs for the treatment of Primary Biliary Cholangitis |
| Q92864604 | Emerging therapies for PBC |
| Q91948597 | Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population |
| Q38600118 | Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. |
| Q90269685 | Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis |
| Q60301070 | Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study |
| Q51137626 | Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. |
| Q38565478 | Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity |
| Q41361892 | Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis |
| Q52648759 | Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). |
| Q38183450 | Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication |
| Q42263045 | Evaluation of nail fold capillaroscopy findings in patients with primary biliary cirrhosis |
| Q91844615 | Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population |
| Q39485889 | Evidence for the association between IgG-antimitochondrial antibody and biochemical response to ursodeoxycholic acid treatment in primary biliary cholangitis |
| Q47156128 | Evidence from a familial case suggests maternal inheritance of primary biliary cholangitis |
| Q91642039 | Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies |
| Q90722135 | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
| Q55332862 | External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. |
| Q39177903 | Extrahepatic Manifestations of Primary Biliary Cholangitis |
| Q84914116 | Extrahepatic conditions associated with primary biliary cirrhosis |
| Q40130719 | Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. |
| Q56971225 | Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis |
| Q38858980 | Finding the cure for primary biliary cholangitis - Still waiting |
| Q38313292 | Gene expression profiles of peripheral blood mononuclear cells in primary biliary cirrhosis |
| Q37089325 | Genetic Association of PTPN22 Polymorphisms with Autoimmune Hepatitis and Primary Biliary Cholangitis in Japan |
| Q37642274 | Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. |
| Q92229185 | Genetic association of E26 transformation specific sequence 1 polymorphisms with the susceptibility of primary biliary cholangitis in China |
| Q43608312 | Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients |
| Q43672317 | Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients |
| Q47827554 | Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. |
| Q36383011 | Genome-Wide Association Studies in Primary Biliary Cirrhosis |
| Q92259854 | Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis |
| Q39034887 | Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population |
| Q28943429 | Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population |
| Q39213467 | Geoepidemiology and changing mortality in primary biliary cholangitis |
| Q47205297 | Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. |
| Q56429943 | Guidelines for the management of primary biliary cirrhosis |
| Q38085065 | Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis |
| Q35309953 | Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis |
| Q55114620 | Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. |
| Q33966083 | Hepatobiliary complications of inflammatory bowel disease |
| Q34147508 | Hepatocyte Death: A Clear and Present Danger |
| Q54469701 | High levels of FCγR3A and PRF1 expression in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. |
| Q42947254 | High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial |
| Q52925804 | High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. |
| Q38554722 | Human autoimmune diseases: a comprehensive update |
| Q44980851 | Human intrahepatic biliary epithelial cells engulf blebs from their apoptotic peers |
| Q46332063 | Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis |
| Q85002108 | Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis |
| Q35131979 | Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving |
| Q33551867 | Human β-Defensin 2 in Primary Sclerosing Cholangitis |
| Q36963978 | Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. |
| Q38957567 | Imaging of autoimmune biliary disease |
| Q24617796 | Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants |
| Q53019283 | Immunologic derangement preceding clinical autoimmunity. |
| Q37877588 | Immunological diseases of the pancreatico-hepatobiliary system: update on etiopathogenesis and cross-sectional imaging findings |
| Q35614763 | Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. |
| Q37559266 | Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient |
| Q52925696 | In recurrent primary biliary cirrhosis after liver transplantation, biliary epithelial cells show increased expression of mitochondrial proteins. |
| Q38374504 | Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis |
| Q38795238 | Incidence of Primary Biliary Cholangitis in a Rural Midwestern Population |
| Q49806997 | Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis |
| Q45173055 | Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis |
| Q36967742 | Increased mean platelet volume is related to histologic severity of primary biliary cirrhosis. |
| Q56766238 | Increased numbers of circulating ICOS⁺ follicular helper T and CD38⁺ plasma cells in patients with newly diagnosed primary biliary cirrhosis |
| Q60309961 | Increased red cell width distribution to lymphocyte ratio is a predictor of histologic severity in primary biliary cholangitis |
| Q48529733 | Inflammatory myopathies associated with anti-mitochondrial antibodies |
| Q37017406 | Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis |
| Q64105140 | Interleukin-33/ST2-Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis |
| Q53098304 | Investigational drugs in phase II clinical trials for primary biliary cholangitis. |
| Q88380162 | Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study |
| Q43155895 | Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis? |
| Q38620686 | It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology |
| Q35631405 | Itch and liver: management in primary care. |
| Q46640079 | Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: "minimal change PBC"? |
| Q39336142 | Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis |
| Q37738636 | Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis |
| Q50097218 | Less Limb Muscle Involvement in Myositis Patients with Anti-Mitochondrial Antibodies |
| Q54254957 | Liver Illness and Psoriatic Patients. |
| Q36320523 | Liver Transplantation for Cholestatic Liver Diseases in Adults |
| Q37743450 | Liver biopsy diagnosis of hepatitis: clues to clinically-meaningful reporting |
| Q37140617 | Liver damage in primary biliary cirrhosis and accompanied by primary Sjögren's syndrome: a retrospective pilot study |
| Q37334112 | Liver diseases in pregnancy: diseases not unique to pregnancy |
| Q38123133 | Liver transplantation and autoimmune liver diseases |
| Q39584105 | Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score |
| Q92685166 | Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study |
| Q38699595 | Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. |
| Q35745075 | Low Serum Hepcidin in Patients with Autoimmune Liver Diseases |
| Q40808835 | Low incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up |
| Q54980590 | Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. |
| Q50142593 | Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis |
| Q55498617 | Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis. |
| Q47787189 | Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome |
| Q40623611 | Management of pruritus in patients with cholestatic liver disease. |
| Q89285900 | Managing PBC: Expanding the Provider Comfort Zone |
| Q36009282 | Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases |
| Q33882608 | Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis |
| Q43013514 | Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid |
| Q36144748 | MiR-139-5p is associated with inflammatory regulation through c-FOS suppression, and contributes to the progression of primary biliary cholangitis. |
| Q41492969 | MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients |
| Q47567609 | Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. |
| Q50130002 | Modern treatment of primary biliary cholangitis |
| Q37631707 | Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis |
| Q36086498 | Molecular diagnostic testing for primary biliary cholangitis |
| Q57119171 | Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist |
| Q88035378 | Monoclonal gammopathy in rheumatic diseases |
| Q46186395 | Mouse model of primary biliary cirrhosis with progressive fibrosis: are we there yet? |
| Q35038847 | Multiple autoimmune propensity and B-non-hodgkin lymphoma: cause or effect? |
| Q41615335 | Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population |
| Q38388403 | Mycobacteria and autoimmunity |
| Q57110523 | NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial |
| Q37355843 | Natural history and management of primary biliary cirrhosis |
| Q26824664 | Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis |
| Q48218121 | New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score |
| Q46182874 | New therapeutics in primary biliary cirrhosis: will there ever be light? |
| Q38261577 | New therapies for primary biliary cirrhosis |
| Q58708624 | Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment |
| Q41042363 | Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases |
| Q44966935 | Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis |
| Q26748613 | Novel bile acid therapeutics for the treatment of chronic liver diseases |
| Q42375647 | Novel strategies and therapeutic options for the management of primary biliary cholangitis |
| Q38342107 | Novel therapeutic targets in primary biliary cirrhosis |
| Q89910702 | Nutritional Management of Cholestasis |
| Q55165714 | Obeticholic Acid: A Farnesoid X Receptor Agonist for Primary Biliary Cholangitis. |
| Q38911238 | Obeticholic acid for the treatment of primary biliary cholangitis |
| Q28072209 | Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection |
| Q38628470 | Obeticholic acid for the treatment of primary biliary cirrhosis |
| Q38626000 | Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. |
| Q50155645 | Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation |
| Q39216355 | Old and new treatments for primary biliary cholangitis |
| Q34415757 | Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis |
| Q28087211 | Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis |
| Q37963978 | Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis |
| Q89538006 | Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges |
| Q57168372 | Osteoporosis in primary biliary cholangitis |
| Q37824300 | Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature |
| Q59384428 | Overlap syndrome: A real syndrome? |
| Q36442097 | Overlapping of primary biliary cirrhosis and small duct primary sclerosing cholangitis: first case report |
| Q87561627 | Oxidative stress and antioxidant status in patients with autoimmune liver diseases |
| Q39782708 | PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis |
| Q37993126 | Pathogenesis and management of pruritus in cholestatic liver disease |
| Q34623557 | Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches |
| Q93140232 | Pathological patterns of biliary disease |
| Q37191674 | Pathway-based analysis of primary biliary cirrhosis genome-wide association studies |
| Q82719034 | Performance parameters of the conventional serological markers for autoimmune hepatitis |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q37681567 | Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid |
| Q24186852 | Pharmacological treatments for primary biliary cirrhosis: a network meta-analysis |
| Q51636366 | Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid |
| Q50003369 | Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis |
| Q38162283 | Polymorphisms in the vitamin D receptor gene and risk of primary biliary cirrhosis: a meta-analysis |
| Q35309882 | Popular and unpopular infectious agents linked to primary biliary cirrhosis. |
| Q48312123 | Possible involvement of chemokine C-C receptor 7- programmed cell death-1+ follicular helper T-cell subset in the pathogenesis of autoimmune hepatitis. |
| Q38063171 | Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What's New? |
| Q64230889 | Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel |
| Q35309854 | Predicting and preventing autoimmunity: the case of anti-mitochondrial antibodies |
| Q47114292 | Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis |
| Q33978160 | Pregnancy with portal hypertension |
| Q89070694 | Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver |
| Q40055616 | Prevalence of pruritus in patients with chronic liver disease: a multicenter study |
| Q89639221 | Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist |
| Q38998320 | Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature |
| Q57114658 | Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization |
| Q39047912 | Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics |
| Q26781780 | Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective |
| Q50954296 | Primary biliary cholangitis associated with warm autoimmune hemolytic anemia. |
| Q90014773 | Primary biliary cholangitis presenting as acute ischemic stroke: A rare association |
| Q64286582 | Primary biliary cholangitis with contemporary presence of anti-mithocondrial and anti-rods and rings autoantibodies: literature first case |
| Q54390436 | Primary biliary cholangitis: new treatments for an old disease. |
| Q56428272 | Primary biliary cirrhosis |
| Q57141930 | Primary biliary cirrhosis |
| Q85213554 | Primary biliary cirrhosis |
| Q36599248 | Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q34637500 | Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis |
| Q26853145 | Primary biliary cirrhosis and liver transplantation |
| Q37266330 | Primary biliary cirrhosis in HBV and HCV patients: Clinical characteristics and outcome |
| Q38192045 | Primary biliary cirrhosis in adults |
| Q50631086 | Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients. |
| Q84773471 | Primary biliary cirrhosis/autoimmune hepatitis overlap syndrome developing in a patient with systemic lupus erythematosus: a case report and review of the literature |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q26853649 | Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy |
| Q35038800 | Primary biliary cirrhosis: family stories |
| Q43987255 | Primary biliary cirrhosis: proposal for a new simple histological scoring system |
| Q38554677 | Primary biliary cirrhosis: safety and benefits of established and emerging therapies |
| Q49712375 | Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report |
| Q37799533 | Primary sclerosing cholangitis: overview and update |
| Q33920325 | Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid |
| Q40311999 | Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study |
| Q83627142 | Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients |
| Q37072380 | Proposed therapies in primary biliary cholangitis |
| Q46933007 | Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis |
| Q38210112 | Pruritus in cholestasis: facts and fiction. |
| Q36134061 | Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis |
| Q35998928 | RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial |
| Q34464043 | Recent advances in the development of farnesoid X receptor agonists |
| Q28076353 | Recent advances in the diagnosis and treatment of primary biliary cholangitis |
| Q33719935 | Recent advances in the management of pruritus in chronic liver diseases |
| Q26748537 | Recent advances in understanding and managing cholestasis |
| Q93140872 | Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation |
| Q36822889 | Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis |
| Q33911547 | Reduced coffee consumption among individuals with primary sclerosing cholangitis but not primary biliary cirrhosis. |
| Q43940290 | Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. |
| Q90126673 | Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis |
| Q37314381 | Refractory pruritus in primary biliary cirrhosis |
| Q38974002 | Reversal of liver cirrhosis: current evidence and expectations |
| Q38174167 | Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q26864272 | Review article: the management of autoimmune hepatitis beyond consensus guidelines |
| Q36369284 | Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? |
| Q55395737 | Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review. |
| Q42363647 | Risk of liver disease in methotrexate treated patients |
| Q26796355 | Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists |
| Q88780685 | Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial |
| Q36248162 | Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? |
| Q95942116 | Roles of trained immunity in the pathogenesis of cholangiopathies: a novel therapeutic target |
| Q41702160 | S100A12 expression in patients with primary biliary cirrhosis |
| Q38837130 | SP140L, an Evolutionarily Recent Member of the SP100 Family, Is an Autoantigen in Primary Biliary Cirrhosis |
| Q37598572 | STAT4 gene polymorphisms are associated with susceptibility and ANA status in primary biliary cirrhosis |
| Q34644916 | Sarcoidosis and primary biliary cirrhosis association: report of a new case |
| Q38390677 | Scandinavian epidemiological research in gastroenterology and hepatology |
| Q46651249 | Scratching the surface of cholestatic itch treatments |
| Q94326725 | Serological tests for primary biliary cholangitis |
| Q55009231 | Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis. |
| Q37725466 | Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma |
| Q36151445 | Serum IgG subclasses in autoimmune diseases |
| Q41933128 | Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases |
| Q41009473 | Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis |
| Q35674098 | Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis |
| Q48145461 | Serum levels of a cell death biomarker predict the development of cirrhosis-related conditions in primary biliary cholangitis. |
| Q34944763 | Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis. |
| Q34408701 | Serum microRNAs as potential biomarkers of primary biliary cirrhosis |
| Q43230366 | Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus |
| Q36014535 | Sex differences associated with primary biliary cirrhosis. |
| Q38190931 | Shear wave elastography for liver stiffness measurement in clinical sonographic examinations: evaluation of intraobserver reproducibility, technical failure, and unreliable stiffness measurements |
| Q48218731 | Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review |
| Q33419647 | Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study |
| Q34303048 | Study of liver cirrhosis over ten consecutive years in Southern China |
| Q33647458 | Subtle presentation of active primary biliary cirrhosis in chronic hepatitis B: a case report |
| Q54936764 | Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort. |
| Q58722495 | Symptoms and health-related quality of life in Japanese patients with primary biliary cholangitis |
| Q52955409 | Synthesis of diastereomerically pure Lys(Nε-lipoyl) building blocks and their use in Fmoc/tBu solid phase synthesis of lipoyl-containing peptides for diagnosis of primary biliary cirrhosis. |
| Q36413970 | Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure |
| Q37526157 | Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion protein |
| Q52624982 | The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. |
| Q46847997 | The Challenges of Nutritional Assessment in Cirrhosis |
| Q35942610 | The Cholangiopathies |
| Q47278009 | The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review |
| Q59384433 | The Diagnosis and Classification of Immune-Mediated Biliary Diseases |
| Q91790202 | The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease |
| Q41303819 | The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis |
| Q40681087 | The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. |
| Q26830032 | The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics |
| Q34438127 | The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid response |
| Q38355697 | The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review |
| Q35833175 | The diagnosis and treatment of primary biliary cirrhosis |
| Q26829493 | The diagnosis of primary biliary cirrhosis |
| Q53237682 | The dynamic and clinical significance of autoantibodies and immunoglobulins in liver transplant recipients. |
| Q37317828 | The dynamic biliary epithelia: molecules, pathways, and disease |
| Q39284642 | The emerging role of mast cells in liver disease |
| Q90293731 | The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis |
| Q35939141 | The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen. |
| Q36573783 | The immunopathology of liver granulomas in primary biliary cirrhosis |
| Q38017976 | The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis |
| Q47285348 | The impact of biopsychosocial factors on quality of life: women with primary biliary cirrhosis on waiting list and post liver transplantation |
| Q37371109 | The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. |
| Q38622370 | The management of autoimmunity in patients with cholestatic liver diseases |
| Q37714640 | The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis |
| Q38037392 | The overlap syndromes of autoimmune hepatitis |
| Q46813053 | The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. |
| Q43589988 | The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice |
| Q88164317 | The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases |
| Q35187219 | The value of MRI in the diagnosis of primary biliary cirrhosis and assessment of liver fibrosis |
| Q90599038 | Therapeutic Effects of Apamin as a Bee Venom Component for Non-Neoplastic Disease |
| Q39816216 | Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis |
| Q38543052 | Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases |
| Q90013058 | Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans |
| Q89509897 | Tight Junction Proteins and the Biology of Hepatobiliary Disease |
| Q55387422 | Toward solving the etiological mystery of primary biliary cholangitis. |
| Q59384465 | Toward the molecular dissection of primary biliary cirrhosis |
| Q54310426 | Towards the serological diagnosis of primary biliary cirrhosis. |
| Q34342199 | Treatment of autoimmune liver disease: current and future therapeutic options |
| Q39314534 | Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. |
| Q64991757 | Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid? |
| Q37777156 | Treatment options for primary sclerosing cholangitis |
| Q90607266 | Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades |
| Q33932461 | Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes |
| Q36417949 | Tuberculosis is not a risk factor for primary biliary cirrhosis: a review of the literature |
| Q36449565 | Twelve-year-old girl with primary biliary cirrhosis |
| Q56934656 | UEG Week 2015 Poster Presentations |
| Q48542369 | Unmet challenges in immune-mediated hepatobiliary diseases |
| Q55190939 | Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis. |
| Q55333522 | Update on pharmacotherapies for cholestatic liver disease. |
| Q37358534 | Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review. |
| Q59810022 | Use of Obeticholic Acid in Patients With Primary Biliary Cholangitis |
| Q46226926 | Using the Icelandic Genealogical Database to define the familial risk of primary biliary cholangitis |
| Q33547476 | Validation of coding algorithms for the identification of patients with primary biliary cirrhosis using administrative data |
| Q82344181 | Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients |
| Q34087671 | Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis |
| Q26745766 | Vitamin D deficiency in patients with liver cirrhosis |
| Q37960398 | Vitamin d deficiency in patients with chronic liver disease and cirrhosis |
| Q33840969 | Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications? |
| Q38252904 | Women and primary biliary cirrhosis |
| Q37249179 | X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome |
| Q83330062 | [Anesthesia in the patient with impaired liver function] |
| Q88019229 | [Extracorporeal therapies in hepatic diseases] |
| Q49999392 | microRevolution in understanding primary biliary cholangitis pathophysiology |
| Q86258230 | β1 integrin is a long-sought sensor for tauroursodeoxycholic acid |
Search more.